Prognostic value of coronary vascular dysfunction assessed by rubidium-82 PET/CT imaging in patients with resistant hypertension without overt coronary artery disease.
Myocardial perfusion reserve
PET/CT
Prognosis
Resistant hypertension
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
14
01
2021
accepted:
01
02
2021
pubmed:
18
2
2021
medline:
18
9
2021
entrez:
17
2
2021
Statut:
ppublish
Résumé
The identification of coronary vascular dysfunction may enhance risk stratification in patients with resistant hypertension (RH). We evaluated if impaired coronary vascular function, assessed by rubidium-82 ( We studied 517 hypertensive subjects, 26% with RH, without overt CAD, and with normal stress-rest myocardial perfusion imaging at Over a median of 38 months (interquartile range 26 to 50), 21 cardiac events (4.1% cumulative event rate) occurred. Patients with RH were older (p < 0.05) and had a higher prevalence of left ventricular hypertrophy (p < 0.001), a lower hyperemic myocardial blood flow (MBF), and myocardial perfusion reserve (MPR) (both p < 0.001) compared to those without. Conversely, coronary artery calcium content and baseline MBF were not different between patients with and without RH. At univariable Cox regression analysis, age, RH, left ventricular ejection fraction, coronary artery calcium score, and reduced MPR were significant predictors of events. At multivariable analysis, age, RH, and reduced MPR (all p < 0.05) were independent predictors of events. Patients with RH and reduced MPR had the highest risk of events and the major risk acceleration over time. The findings suggest that the assessment of coronary vascular function may enhance risk stratification in patients with hypertension.
Identifiants
pubmed: 33594472
doi: 10.1007/s00259-021-05239-w
pii: 10.1007/s00259-021-05239-w
pmc: PMC8426234
doi:
Substances chimiques
Rubidium Radioisotopes
0
Rubidium-82
9K730EL8KU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3162-3171Informations de copyright
© 2021. The Author(s).
Références
J Am Coll Cardiol. 2009 Jul 7;54(2):150-6
pubmed: 19573732
Eur Heart J Cardiovasc Imaging. 2019 Dec 1;20(12):1379-1387
pubmed: 31302673
Circulation. 2012 Apr 3;125(13):1594-6
pubmed: 22379111
Circulation. 2012 Apr 3;125(13):1635-42
pubmed: 22379110
J Am Coll Cardiol. 2013 May 21;61(20):2098-106
pubmed: 23524053
N Engl J Med. 2007 Feb 22;356(8):830-40
pubmed: 17314342
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Clin Res Cardiol. 2017 Feb;106(2):151-157
pubmed: 27747373
Can J Cardiol. 1996 Oct;12(10):959-64
pubmed: 9191487
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Circulation. 2002 Jan 29;105(4):539-42
pubmed: 11815441
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
J Nucl Cardiol. 2010 Aug;17(4):600-16
pubmed: 20387135
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
J Nucl Cardiol. 2020 Apr;27(2):534-541
pubmed: 29679222
JACC Cardiovasc Imaging. 2009 Jul;2(7):846-54
pubmed: 19608135
Eur Heart J. 2018 Mar 7;39(10):840-849
pubmed: 29293969
Hypertension. 2018 Nov;72(5):e53-e90
pubmed: 30354828
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1129-1135
pubmed: 28293706
Eur Heart J Cardiovasc Imaging. 2019 Aug 1;20(8):949-958
pubmed: 30768182
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Hypertens Res. 1999 Nov;22(4):291-5
pubmed: 10580396
Cardiology. 1993;83(5-6):298-303
pubmed: 8111762
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1037-47
pubmed: 22398957
JACC Cardiovasc Imaging. 2012 Oct;5(10):1025-34
pubmed: 23058070
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2290-2298
pubmed: 28815291
Circulation. 2012 Oct 9;126(15):1858-68
pubmed: 22919001
Hypertension. 2007 Jul;50(1):204-11
pubmed: 17470716
JACC Cardiovasc Imaging. 2010 Jun;3(6):623-40
pubmed: 20541718
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):521-529
pubmed: 29372272